{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:27:06Z","timestamp":1760866026855,"version":"3.41.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pharep.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,1,15]],"date-time":"2017-01-15T10:02:22Z","timestamp":1484474542000},"page":"492-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions"],"prefix":"10.1007","volume":"69","author":[{"given":"Devender","family":"Kodati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narsimhareddy","family":"Yellu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2017.01.006_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jcrc.2013.10.004","article-title":"Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis","volume":"29","author":"Kitsios","year":"2014","journal-title":"J Crit Care"},{"key":"10.1016\/j.pharep.2017.01.006_bib0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0091270003254575","article-title":"Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers","volume":"43","author":"Klausner","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2017.01.006_bib0015","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.msec.2015.09.062","article-title":"Rapid determination of furosemide in drug and blood plasma of wrestlers by a carboxy-MWCNT sensor","volume":"58","author":"Heidarimoghadam","year":"2016","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"10.1016\/j.pharep.2017.01.006_bib0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14656566.2014.879117","article-title":"Diuretics in the treatment of hypertension: part 2: loop diuretics and potassium-sparing agents","volume":"15","author":"Tamargo","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharep.2017.01.006_bib0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3747\/pdi.2014.00328","article-title":"Pharmacokinetic and dynamic of furosemide in peritoneal dialysis patients","volume":"36","author":"Lamarche","year":"2016","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.pharep.2017.01.006_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5049\/EBP.2015.13.1.17","article-title":"Loop diuretics in clinical practice","volume":"13","author":"Oh","year":"2015","journal-title":"Electrolyte Blood Press"},{"key":"10.1016\/j.pharep.2017.01.006_bib0035","doi-asserted-by":"crossref","first-page":"958 9","DOI":"10.1152\/ajprenal.00476.2015","article-title":"Everything we always wanted to know about furosemide but were afraid to ask","volume":"310","author":"Huang","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharep.2017.01.006_bib0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1381612820666141024151119","article-title":"Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches","volume":"21","author":"Zisaki","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharep.2017.01.006_bib0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00228-015-1864-5","article-title":"Development of population pharmacokinetic model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect","volume":"71","author":"Hu","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2017.01.006_bib0050","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1128\/AAC.02430-12","article-title":"Development of a population pharmacokinetic model to describe azithromycin wholeblood and plasma concentrations over time in healthy subjects","volume":"57","author":"Pene","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharep.2017.01.006_bib0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/j.1552-4604.1996.tb04196.x","article-title":"The effects of epoprostenol on drug disposition. II: a pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure","volume":"36","author":"Carlton","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2017.01.006_bib0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0009-9236(96)90170-8","article-title":"Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration","volume":"60","author":"Wakelkamp","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2017.01.006_bib0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2125.1998.00802.x","article-title":"The influence of drug input rate on the development of tolerance to frusemide","volume":"46","author":"Wakelkamp","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2017.01.006_bib0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1067\/mcp.2002.127608","article-title":"Development of an optimal furosemide infusion strategy in infants with modeling and simulation","volume":"72","author":"Schoemaker","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2017.01.006_bib0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/bdd.1874","article-title":"Population-based meta-analysis of furosemide pharmacokinetics","volume":"35","author":"Van Wart","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharep.2017.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/aps.2012.114","article-title":"A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects","volume":"33","author":"Feng","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharep.2017.01.006_bib0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40261-015-0371-x","article-title":"Population pharmacokinetic modeling of tapentadol extended release (ER) in healthy subjects and patients with moderate or severe pain","volume":"36","author":"Huntjens","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pharep.2017.01.006_bib0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2016.02.019","article-title":"The kidneys play a central role in the clearance of rhGH in rats","volume":"86","author":"Vestergaard","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharep.2017.01.006_bib0095","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/dmd.112.050112","article-title":"Population pharmacokinetic analysis of daikenchuto, a traditional Japanese medicine (Kampo) in Japanese and US health volunteers","volume":"41","author":"Munekage","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2017.01.006_bib0100","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2017.01.006_bib0105","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000001823","article-title":"Determinants of urinary output response to IV furosemide in acute kidney injury: a Pharmacokinetic\/Pharmacodynamic study","author":"Silbert","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharep.2017.01.006_bib0110","first-page":"271","article-title":"Changes in pharmacokinetics and in effect of furosemide in the elderly","volume":"5","author":"Kerremans","year":"1983","journal-title":"Clin Exp Hypertens A"},{"key":"10.1016\/j.pharep.2017.01.006_bib0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","article-title":"Furosemide (frusemide): a pharmacokinetic\/pharmacodynamic review (part I)","volume":"18","author":"Boles-Ponto","year":"1990","journal-title":"Clin Pharmacokinet"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017300233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017300233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:51Z","timestamp":1752611811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2017.01.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1734114017300233"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2017.01.006","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.","name":"copyright","label":"Copyright"}]}}